You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
信立泰(002294.SZ):SAL0114片臨牀試驗申請獲得受理
格隆匯 12-07 19:43

格隆匯12月7日丨信立泰(002294.SZ)公佈,近日,公司研發的“SAL0114臨牀試驗申請獲得國家藥品監督管理局受理。

SAL0114 系公司自主研發,擬申請適應症為重度抑鬱 抑鬱症是一種常見的精神疾病,患病率高、複發率高、致殘率高。研究顯示我國抑鬱症的患病率達到2.1%中國成人抑鬱障礙終生患病率為6.8%,且抑鬱障礙患者衞生服務利用率低,很少獲得充分治療。目前已上市的抗抑鬱藥物,大多起效需要數週,存在未被滿足的臨牀需求。隨着生活水平的提高及羣眾健康意識的增強,預計抑鬱症的市場仍將不斷擴大。SAL0114片若能研發成功獲批上市,將進一步滿足潛在的臨牀需求為患者提供更多用藥選擇

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account